Abstract:Abstract Development of new drugs is of high interest for the field of cardiac and cardiovascular diseases, which are a dominant cause of death worldwide. Before being allowed to be used and distributed, every new potentially therapeutic compound must be strictly validated during preclinical and clinical trials. The preclinical studies usually involve the in vitro and in vivo evaluation. Due to the increasing reporting of discrepancy in drug effects in animal and humans and the requirement to reduce the number of animals used in research, improvement of in vitro models based on human cells is indispensable. Primary cardiac cells are difficult to access and maintain in cell culture for extensive experiments; therefore, the human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) became an excellent alternative. This technology enables a production of high number of patient- and disease-specific cardiomyocytes and other cardiac cell types for a large-scale research. The drug effects can be extensively evaluated in the context of electrophysiological responses with a use of well-established tools, such as multielectrode array (MEA), patch clamp, or calcium ion oscillation measurements. Cardiotoxicity, which is a common reason for withdrawing drugs from marketing or rejection at final stages of clinical trials, can be easily verified with a use of hiPSC-CM model providing a prediction of human-specific responses and higher safety of clinical trials involving patient cohort. Abovementioned studies can be performed using two-dimensional cell culture providing a high-throughput and relatively lower costs. On the other hand, more complex structures, such as engineered heart tissue, organoids, or spheroids, frequently applied as co-culture systems, represent more physiological conditions and higher maturation rate of hiPSC-derived cells. Furthermore, heart-on-a-chip technology has recently become an increasingly popular tool, as it implements controllable culture conditions, application of various stimulations and continuous parameters read-out. This paper is an overview of possible use of cardiomyocytes and other cardiac cell types derived from hiPSC as in vitro models of heart in drug research area prepared on the basis of latest scientific reports and providing thorough discussion regarding their advantages and limitations.

Designer Assays for Your Sick, Subdivided Heart

Engineering Human Ventricular Heart Muscles Based on a Highly Efficient System for Purification of Human Pluripotent Stem Cell-Derived Ventricular Cardiomyocytes

Design and fabrication of an integrated heart-on-a-chip platform for construction of cardiac tissue from human iPSC-derived cardiomyocytes and in situ evaluation of physiological function

Biomimetic Cardiac Microsystems for Pathophysiological Studies and Drug Screens

Engineered platforms for mimicking cardiac development and drug screening

Heart-on-a-chip systems with tissue-specific functionalities for physiological, pathological, and pharmacological studies

Engineering Cardiac Tissue for Advanced Heart‐on‐a‐chip Platforms

Establishment of a heart-on-a-chip microdevice based on human iPS cells for the evaluation of human heart tissue function

Micro‐Engineered Heart Tissues on‐Chip with Heterotypic Cell Composition Display Self‐Organization and Improved Cardiac Function

Fabrication and Biomedical Applications of Heart-on-a-chip

Development of a cardiotoxicity evaluation system using a Heart-on-a-Chip Microdevice with aligned fiber device

Ultrathin and Flexible Bioelectronic Arrays for Functional Measurement of iPSC-Cardiomyocytes under Cardiotropic Drug Administration and Controlled Microenvironments

Human-induced pluripotent stem cell-derived cardiomyocytes, 3D cardiac structures, and heart-on-a-chip as tools for drug research

Functional Engineered Human Cardiac Patches Prepared from Nature's Platform Improve Heart Function after Acute Myocardial Infarction.

Combined Effects of Electric Stimulation and Microgrooves in Cardiac Tissue‐on‐a‐Chip for Drug Screening

A patterned human primitive heart organoid model generated by pluripotent stem cell self-organization

Engineering a living cardiac pump on a chip using high-precision fabrication

Organ-on-a-chip technology: a novel approach to investigate cardiovascular diseases

Organ‐on‐a‐Chip: A Heart‐Breast Cancer‐on‐a‐Chip Platform for Disease Modeling and Monitoring of Cardiotoxicity Induced by Cancer Chemotherapy (Small 15/2021)

A heart-on-a-chip platform for online monitoring of contractile behavior via digital image processing and piezoelectric sensing technique

A Platform for Generation of Chamber-Specific Cardiac Tissues and Disease Modeling